A receptor-targeting antibody
Bimagrumab binds ActRIIA and ActRIIB and blocks ligand binding. Its target differs from that of GLP-1 receptor agonists. Lilly’s published development pipeline lists it in phase 2 for obesity.
Lilly · Clinical development pipelineWhy researchers are interested
Receptor biology provides a way to ask how signalling influences tissues and how those pathways can be measured. A useful research question specifies the model, the endpoint and the comparator before a material is selected.
The clinical literature is one part of that background. It should be read alongside preclinical evidence and the requirements of the specific laboratory application, rather than treated as a product specification.
Bimagrumab and semaglutide
These agents have been studied in combination in the BELIEVE trial. A combination result needs to be interpreted in relation to the individual study groups, not assumed to describe either agent alone.
Read our guide to the BELIEVE study.
Evaluating research material
For laboratory procurement, establish the material’s identity and your application requirements. Request the proposed manufacturer, formulation, analytical methods and batch documentation. These details are not yet confirmed for this project’s planned catalogue addition.